A Phase 1 interventional study of TV-46046 and Depo-subQ Provera in Contraception, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 3 sites in 2 countries. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-26.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate and compare the pharmacokinetic profile of Medroxyprogesterone acetate following subcutaneous administration of 3 different doses of TV-46046 and a dose of Depo-subQ Provera in healthy female participants.
The secondary objectives of the study are to evaluate and compare the safety, local tolerability, and acceptability of a subcutaneous injection of 3 different doses of TV-46046 and a dose of Depo-subQ Provera in healthy female participants.
The total duration of the study for each participant is expected to be up to 19.5 months.
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
NOTE- Additional criteria apply, please contact the investigator for more information.
Exclusion Criteria:
NOTE- Additional criteria apply, please contact the investigator for more information.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: TV-46046
Drug: TV-46046
Drug: TV-46046
Drug: Depo-subQ Provera
SC injection of 300 mg/mL (120 mg/0.4mL; 180 mg/0.6mL; 240 mg/0.8mL)
SC injection of 104 mg/0.65 mL
Maximum Observed Serum Concentration (Cmax) of Medroxyprogesterone Acetate (MPA)
Time frame: Day 0 to Day 365
Time to Reach Cmax (Tmax) of MPA
Time frame: Day 0 to Day 365
Serum MPA Concentration at Day 91 (C91)
Time frame: Day 91
Serum MPA Concentration at Day 182 (C182)
Time frame: Day 182
Serum MPA Concentration at Day 210 (C210)
Time frame: Day 210
Area Under the Serum Drug Concentration-Time Curve From Time 0 to Day 182 (AUC0-182) of MPA
Time frame: Day 0 to Day 182
Area Under the Serum Drug Concentration-Time Curve From Time 0 to Day 210 (AUC0-210) of MPA
Time frame: Day 0 to Day 210
Area Under the Serum Drug Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MPA
Time frame: Day 0 to Day 365
Apparent Terminal Half-life (t½) of MPA
Time frame: Day 0 to Day 365
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: Day 0 up to Week 78
Number of Participants With at Least 1 Concomitant Medication Use During Treatment
Concomitant medications included acetic acid derivatives and substances, aminoalkyl ethers, anilides, calcium compounds, other viral vaccines, and propionic acid derivatives etc.
Time frame: Day 0 up to Week 78
Number of Participants With Clinically Significant Changes in Vital Signs
Vital signs examination included blood pressure, respiration rate, pulse, and body temperature.
Time frame: Day 0 to Day 365
Change From Baseline in Body Weight at Day 7 and Weeks 13, 26, and 52
Time frame: Day 7 and Weeks 13, 26, and 52
Number of Participants With Overall Opinion of Vaginal Bleeding Pattern
Number of participants with overall opinion of vaginal bleeding pattern as acceptable or not acceptable has been reported.
Time frame: Weeks 13, 26, and 52
Number of Participants With Patient Health Questionnaire (PHQ-9) Mood Scores
The PHQ-9 is a participant-rated depressive symptom severity scale to monitor severity over time for newly diagnosed participants or participants in current treatment for depression. Scoring was based on participants' responses to each of the 9 questions, as follows: 0=not at all; 1=several days; 2=more than half the days; and 3=nearly every day. The PHQ-9 total score was calculated as the sum of the 9 individual item scores. The PHQ-9 total score was categorized as follows: 0 = no depression, 1 to 4=minimal depression, 5 to 9=mild depression, 10 to 14=moderate depression, 15 to 19=moderately severe depression; and 20 to 27=severe depression. Higher scores indicate more severe depression.
Time frame: Baseline, Weeks 4, 13, 26, and 52
Number of Participants With Clinically Significant Changes in Liver Function Tests
Time frame: Day 0 to Day 365
Estradiol Concentrations
Time frame: Baseline, Weeks 4, 13, 26, 30, and 52
Number of Participants With No Ovulation in 12 Months
Ovulation was defined as one or more progesterone measurements ≥ 4.7 ng/mL in Weeks 48, 49, 50, 51 or 52.
Time frame: 12 months
Number of Participants With 1 or More Injection Site Reactions (ISRs)
The ISRs included erythema, swelling, pruritus, bleeding, tenderness, bruising, hypopigmentation, atrophy, and injection site pain.
Time frame: Day 0 to Day 365
Number of Participants With Responses to the Acceptability Question (What do You Like About the Method?)
Acceptability questions include likes and dislikes of the method and willingness to use the product in the future.
Time frame: Weeks 26 and 52
Number of Participants With Responses to the Acceptability Question (What do You Not Like About the Method?)
Acceptability questions include likes and dislikes of the method and willingness to use the product in the future.
Time frame: Weeks 26 and 52
Number of Participants With Responses to the Acceptability Question (If You Were at Risk for Pregnancy, Would You Use This Method of Contraception Outside of This Study?)
Acceptability questions include likes and dislikes of the method and willingness to use the product in the future.
Time frame: Weeks 26 and 52
Number of Participants With Responses to the Acceptability Question (If You Had a Choice, Which Injectable Contraceptive Method Would You Prefer?)
Acceptability questions include likes and dislikes of the method and willingness to use the product in the future.
Time frame: Weeks 26 and 52
Progesterone Concentration
Time frame: Weeks 48, 49, 50, 51, and 52
| Milestone | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Started | 16 | 15 | 14 | 15 |
| Received at least 1 dose of study drug | 16 | 15 | 14 | 15 |
| Completed | 16 | 13 | 14 | 14 |
| Not completed | 0 | 2 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 1 |
| Withdrew: Personal reasons | 0 | 1 | 0 | 0 |
| nanograms (ng)/ milliliter (mL) | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Maximum Observed Serum Concentration (Cmax) of Medroxyprogesterone Acetate (MPA) | 0.940 ± 41.187 | 1.180 ± 39.076 | 1.750 ± 41.407 | 0.963 ± 47.672 |
| days | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Time to Reach Cmax (Tmax) of MPA | 17.0 (1.0 to 105.0) | 28.0 (1.0 to 71.0) | 6.0 (2.0 to 336.0) | 31.5 (1.0 to 105.0) |
| ng/mL | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Serum MPA Concentration at Day 91 (C91) | 0.570 ± 36.802 | 0.660 ± 49.360 | 1.090 ± 40.151 | 0.474 ± 37.765 |
| ng/mL | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Serum MPA Concentration at Day 182 (C182) | 0.201 ± 69.429 | 0.279 ± 65.793 | 0.443 ± 60.531 | 0.118 ± 150.789 |
| ng/mL | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Serum MPA Concentration at Day 210 (C210) | 0.119 ± 105.727 | 0.208 ± 76.683 | 0.365 ± 69.357 | 0.063 ± 244.107 |
| days*ng/mL | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Area Under the Serum Drug Concentration-Time Curve From Time 0 to Day 182 (AUC0-182) of MPA | 94.2 ± 27.0 | 121.8 ± 38.1 | 173.6 ± 25.8 | 86.1 ± 29.6 |
| days*ng/mL | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Area Under the Serum Drug Concentration-Time Curve From Time 0 to Day 210 (AUC0-210) of MPA | 100.2 ± 23.9 | 129.6 ± 37.8 | 187.0 ± 26.0 | 90.1 ± 27.6 |
| days*ng/mL | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Area Under the Serum Drug Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of MPA | 117.2 ± 17.9 | 160.8 ± 36.6 | 224.9 ± 18.9 | 105.1 ± 19.5 |
| days | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Apparent Terminal Half-life (t½) of MPA | 47.4 (18.7 to 114.8) | 85.3 (15.7 to 160.2) | 79.8 (19.4 to 130.4) | 37.4 (8.2 to 224.3) |
| Participants | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 11 | 10 | 8 | 12 |
Concomitant medications included acetic acid derivatives and substances, aminoalkyl ethers, anilides, calcium compounds, other viral vaccines, and propionic acid derivatives etc.
| Participants | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Number of Participants With at Least 1 Concomitant Medication Use During Treatment | 11 | 8 | 6 | 10 |
Vital signs examination included blood pressure, respiration rate, pulse, and body temperature.
| Participants | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Vital Signs | 0 | 0 | 0 | 0 |
| kilograms (kg) | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Change at Day 7 | -0.21 ± 0.19 | -0.27 ± 0.20 | -0.33 ± 0.17 | 0.05 ± 0.28 |
| Change at Week 13 | -1.10 ± 1.42 | 0.92 ± 0.65 | 0.84 ± 0.35 | 1.40 ± 0.87 |
| Change at Week 26 | 1.14 ± 0.58 | 2.91 ± 1.11 | 1.38 ± 0.74 | 2.68 ± 0.89 |
| Change at Week 52 | 0.60 ± 0.56 | 1.38 ± 1.00 | 0.79 ± 1.06 | 1.99 ± 0.91 |
Number of participants with overall opinion of vaginal bleeding pattern as acceptable or not acceptable has been reported.
| Participants | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Week 13 — Acceptable | 10 | 9 | 11 | 11 |
| Week 13 — Not Acceptable | 6 | 5 | 3 | 4 |
| Week 26 — Acceptable | 12 | 13 | 9 | 12 |
| Week 26 — Not Acceptable | 4 | 1 | 4 | 1 |
| Week 52 — Acceptable | 14 | 12 | 13 | 13 |
| Week 52 — Not Acceptable | 2 | 1 | 1 | 1 |
The PHQ-9 is a participant-rated depressive symptom severity scale to monitor severity over time for newly diagnosed participants or participants in current treatment for depression. Scoring was based on participants' responses to each of the 9 questions, as follows: 0=not at all; 1=several days; 2=more than half the days; and 3=nearly every day. The PHQ-9 total score was calculated as the sum of the 9 individual item scores. The PHQ-9 total score was categorized as follows: 0 = no depression, 1 to 4=minimal depression, 5 to 9=mild depression, 10 to 14=moderate depression, 15 to 19=moderately severe depression; and 20 to 27=severe depression. Higher scores indicate more severe depression.
| Participants | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Baseline — No Depression | 12 | 9 | 10 | 9 |
| Baseline — Minimal Depression | 4 | 4 | 3 | 5 |
| Baseline — Mild Depression | 0 | 2 | 1 | 1 |
| Baseline — Moderate Depression | 0 | 0 | 0 | 0 |
| Baseline — Moderately Severe Depression | 0 | 0 | 0 | 0 |
| Baseline — Severe Depression | 0 | 0 | 0 | 0 |
| Week 4 — No Depression | 9 | 10 | 9 | 6 |
| Week 4 — Minimal Depression | 5 | 4 | 3 | 7 |
| Week 4 — Mild Depression | 1 | 1 | 1 | 1 |
| Week 4 — Moderate Depression | 1 | 0 | 0 | 1 |
| Week 4 — Moderately Severe Depression | 0 | 0 | 1 | 0 |
| Week 4 — Severe Depression | 0 | 0 | 0 | 0 |
| Week 13 — No Depression | 8 | 6 | 9 | 9 |
| Week 13 — Minimal Depression | 6 | 7 | 5 | 4 |
| Week 13 — Mild Depression | 2 | 2 | 0 | 1 |
| Week 13 — Moderate Depression | 0 | 0 | 0 | 1 |
| Week 13 — Moderately Severe Depression | 0 | 0 | 0 | 0 |
| Week 13 — Severe Depression | 0 | 0 | 0 | 0 |
| Week 26 — No Depression | 10 | 7 | 10 | 10 |
| Week 26 — Minimal Depression | 4 | 5 | 2 | 2 |
| Week 26 — Mild Depression | 2 | 2 | 1 | 1 |
| Week 26 — Moderate Depression | 0 | 0 | 0 | 0 |
| Week 26 — Moderately Severe Depression | 0 | 0 | 0 | 0 |
| Week 26 — Severe Depression | 0 | 0 | 0 | 0 |
| Week 52 — No Depression | 11 | 6 | 10 | 12 |
| Week 52 — Minimal Depression | 4 | 5 | 3 | 2 |
| Week 52 — Mild Depression | 1 | 1 | 0 | 0 |
| Week 52 — Moderate Depression | 0 | 1 | 0 | 0 |
| Week 52 — Moderately Severe Depression | 0 | 0 | 1 | 0 |
| Week 52 — Severe Depression | 0 | 0 | 0 | 0 |
| Participants | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Number of Participants With Clinically Significant Changes in Liver Function Tests | 0 | 0 | 0 | 0 |
| picograms (pg)/mL | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Baseline | 64.988 ± 57.169 | 52.825 ± 22.857 | 63.962 ± 74.815 | 66.181 ± 64.843 |
| Week 4 | 72.357 ± 38.855 | 49.027 ± 48.373 | 31.149 ± 13.394 | 55.699 ± 28.077 |
| Week 13 | 62.389 ± 56.316 | 45.890 ± 30.475 | 36.337 ± 25.065 | 42.071 ± 30.137 |
| Week 26 | 114.347 ± 67.997 | 177.369 ± 197.661 | 52.132 ± 38.971 | 105.234 ± 67.421 |
| Week 30 | 133.892 ± 138.964 | 77.861 ± 58.685 | 81.301 ± 58.232 | 142.691 ± 163.819 |
| Week 52 | 122.994 ± 108.549 | 171.966 ± 166.209 | 148.441 ± 140.495 | 103.951 ± 63.290 |
Ovulation was defined as one or more progesterone measurements ≥ 4.7 ng/mL in Weeks 48, 49, 50, 51 or 52.
| Participants | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Number of Participants With No Ovulation in 12 Months | 4 | 7 | 8 | 3 |
The ISRs included erythema, swelling, pruritus, bleeding, tenderness, bruising, hypopigmentation, atrophy, and injection site pain.
| Participants | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Number of Participants With 1 or More Injection Site Reactions (ISRs) | 7 | 6 | 6 | 4 |
Acceptability questions include likes and dislikes of the method and willingness to use the product in the future.
| Participants | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Week 26: Easy to use | 7 | 7 | 7 | 8 |
| Week 26: Weight gain | 2 | 1 | 4 | 1 |
| Week 26: Weight loss | 1 | 1 | 0 | 0 |
| Week 26: Menstrual changes | 6 | 5 | 3 | 5 |
| Week 26: Discreet | 8 | 8 | 4 | 5 |
| Week 26: Provides longer-term protection than other method | 6 | 4 | 4 | 3 |
| Week 26: Few side effects | 5 | 5 | 6 | 2 |
| Week 26: Has to be administered by a healthcare provider | 2 | 3 | 2 | 3 |
| Week 26: Nothing | 1 | 0 | 0 | 0 |
| Week 26: Other | 1 | 1 | 0 | 1 |
| Week 52: Easy to use | 13 | 11 | 10 | 11 |
| Week 52: Weight gain | 2 | 4 | 3 | 1 |
| Week 52: Weight loss | 2 | 1 | 0 | 0 |
| Week 52: Menstrual changes | 5 | 4 | 3 | 4 |
| Week 52: Discreet | 7 | 6 | 6 | 9 |
| Week 52: Provides longer-term protection than other method | 7 | 8 | 3 | 10 |
| Week 52: Few side effects | 10 | 5 | 7 | 6 |
| Week 52: Has to be administered by a healthcare provider | 2 | 2 | 1 | 2 |
| Week 52: Nothing | 0 | 1 | 0 | 0 |
| Week 52: Other | 0 | 0 | 0 | 0 |
Acceptability questions include likes and dislikes of the method and willingness to use the product in the future.
| Participants | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Week 26: Pain at injection | 2 | 1 | 3 | 1 |
| Week 26: Once injected, it cannot be reversed | 2 | 1 | 0 | 0 |
| Week 26: Weight gain | 1 | 6 | 5 | 6 |
| Week 26: Weight loss | 0 | 0 | 0 | 0 |
| Week 26: Nothing | 5 | 2 | 2 | 5 |
| Week 26: Menstrual changes | 7 | 6 | 8 | 4 |
| Week 26: Injection site reactions | 0 | 0 | 0 | 0 |
| Week 26: Other side effects | 3 | 0 | 0 | 1 |
| Week 26: Other | 0 | 0 | 0 | 1 |
| Week 52: Pain at injection | 2 | 2 | 2 | 1 |
| Week 52: Once injected, it cannot be reversed | 4 | 3 | 0 | 0 |
| Week 52: Weight gain | 1 | 4 | 6 | 6 |
| Week 52: Weight loss | 1 | 0 | 0 | 0 |
| Week 52: Nothing | 5 | 1 | 3 | 5 |
| Week 52: Menstrual changes | 8 | 8 | 6 | 3 |
| Week 52: Injection site reactions | 1 | 2 | 1 | 0 |
| Week 52: Other side effects | 1 | 2 | 0 | 1 |
| Week 52: Other | 0 | 0 | 0 | 0 |
Acceptability questions include likes and dislikes of the method and willingness to use the product in the future.
| Participants | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Week 26 — Yes | 4 | 2 | 2 | 3 |
| Week 26 — No | 11 | 10 | 10 | 9 |
| Week 52 — Yes | 2 | 2 | 3 | 2 |
| Week 52 — No | 14 | 10 | 11 | 12 |
Acceptability questions include likes and dislikes of the method and willingness to use the product in the future.
| Participants | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Week 26 — Injection every 1 month | 0 | 1 | 0 | 0 |
| Week 26 — Injection every 3 months | 3 | 3 | 3 | 2 |
| Week 26 — Injection every 6 months | 6 | 5 | 5 | 4 |
| Week 26 — Injection every 12 months | 5 | 3 | 5 | 5 |
| Week 26 — Frequency of reinjections is not important | 2 | 0 | 0 | 2 |
| Week 52 — Injection every 1 month | 0 | 0 | 0 | 0 |
| Week 52 — Injection every 3 months | 3 | 2 | 2 | 1 |
| Week 52 — Injection every 6 months | 2 | 4 | 3 | 5 |
| Week 52 — Injection every 12 months | 10 | 6 | 7 | 6 |
| Week 52 — Frequency of reinjections is not important | 1 | 1 | 1 | 2 |
| ng/mL | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Week 48 | 2.103 ± 3.993 | 0.945 ± 2.422 | 2.255 ± 4.395 | 2.682 ± 3.900 |
| Week 49 | 1.803 ± 3.268 | 2.448 ± 3.784 | 1.593 ± 3.471 | 4.323 ± 5.276 |
| Week 50 | 4.793 ± 6.791 | 5.224 ± 7.554 | 1.649 ± 3.085 | 3.086 ± 5.312 |
| Week 51 | 4.280 ± 7.133 | 0.795 ± 0.928 | 1.214 ± 2.737 | 1.669 ± 3.390 |
| Week 52 | 2.096 ± 4.319 | 2.264 ± 4.167 | 2.561 ± 5.069 | 2.529 ± 4.152 |
Collected over Day 0 up to Week 78. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TV46046 Dose A | 0/16 (0%) | 0/16 (0%) | 11/16 (68.8%) |
| TV46046 Dose B | 0/15 (0%) | 0/15 (0%) | 10/15 (66.7%) |
| TV46046 Dose C | 0/14 (0%) | 0/14 (0%) | 8/14 (57.1%) |
| Depo-subQ Provera | 0/15 (0%) | 1/15 (6.7%) | 12/15 (80%) |
| Event | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| Bile duct stoneHepatobiliary disorders | 0/16 | 0/15 | 0/14 | 1/15 |
| Event | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera |
|---|---|---|---|---|
| HeadacheNervous system disorders | 6/16 | 2/15 | 1/14 | 4/15 |
| FatigueGeneral disorders | 2/16 | 2/15 | 1/14 | 1/15 |
| NasopharyngitisInfections and infestations | 0/16 | 0/15 | 0/14 | 2/15 |
| Injection site painGeneral disorders | 2/16 | 1/15 | 1/14 | 1/15 |
| Increased appetiteMetabolism and nutrition disorders | 2/16 | 0/15 | 0/14 | 0/15 |
| Breast painReproductive system and breast disorders | 2/16 | 0/15 | 0/14 | 0/15 |
| Injection site erythemaGeneral disorders | 1/16 | 0/15 | 1/14 | 0/15 |
| Bronchitis viralInfections and infestations | 0/16 | 0/15 | 1/14 | 0/15 |
| COVID-19Infections and infestations | 0/16 | 0/15 | 1/14 | 1/15 |
| FuruncleInfections and infestations | 0/16 | 0/15 | 1/14 | 1/15 |
Safety analysis set included all randomized participants who received an injection of study drug.
| Age, Continuous(years) | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera | Total |
|---|---|---|---|---|---|
| Mean | 35.3 ± 6.1 | 33.9 ± 7.2 | 31.2 ± 7.2 | 32.9 ± 6.3 | 33.4 ± 6.7 |
| Sex: Female, Male(Participants) | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera | Total |
|---|---|---|---|---|---|
| Female | 16 | 15 | 14 | 15 | 60 |
| Male | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | TV46046 Dose A | TV46046 Dose B | TV46046 Dose C | Depo-subQ Provera | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 4 | 1 | 5 | 11 |
| White | 8 | 4 | 5 | 4 | 21 |
| More than one race | 7 | 7 | 7 | 6 | 27 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Upon primary clinical trial manuscript publication, researchers may request access to underlying study data. Each accepted article must be accompanied by a Data Availability Statement that describes where any primary data, associated metadata, original software, and any additional relevant materials necessary to understand, assess, and replicate the reported study findings in totality can be found. Underlying study data will be de-identified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information. Requests will be reviewed for scientific merit, product approval status, and conflicts of interest. Please email manuscript primary author to make your request.
Ran from Dec 2020 to primary completion in Jul 2022, 18 months.
Results were first posted in Feb 2024, 1 year 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Medroxyprogesterone Acetate
Teva Branded Pharmaceutical Products R&D, Inc. →